UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of

UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the
75th Annual Meeting of the College on Problems of Drug Dependence

Leading Addiction Researchers Discuss MN-166 in Symposium on New Approaches in
Addiction Treatment

SAN DIEGO, June 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code
Number: 4875), today announced the presentation of preliminary results from a
Phase 1b study of MN-166 (ibudilast) in methamphetamine addiction at the 75^th
Annual Meeting of the College on Problems of Drug Dependence (CPDD) in San
Diego on June 18, 2013. MN-166 was featured in both a poster session and a
symposium at the meeting where leading researchers discussed the role of
activated glia, and potential intervention with glial attenuators like MN-166,
in drug abuse.Pre-clinical and early clinical results were summarized in the
symposium session.

"We are excited to present the results of our initial analyses of data from
our trial showing MN-166 does not cause significant changes in cardiovascular
functioning in the presence of relevant doses of methamphetamine in people
living with methamphetamine addiction.We are additionally encouraged with the
discussion at the symposium of the strong potential for glial attenuators,
like MN-166, to provide a novel approach to fighting drug addictions," said
Steven Shoptaw, Ph.D., Professor, UCLA Departments of Family Medicine and
Psychiatry and Biobehavioral Sciences and principle investigator of the trial.
"Methamphetamine is toxic to the brain. MN-166 may act by reducing
methamphetamine's neurotoxic inflammation and attenuating other actions
contributing to dependence."

"MN-166 is a novel and exciting approach to treating drug addiction," said
co-investigator Keith Heinzerling, M.D., Assistant Professor, UCLA Department
of Family Medicine, Medical Director, UCLA Center for Behavioral and Addiction
Medicine. "We look forward to initiating later this summer a National
Institute on Drug Abuse-funded Phase 2 trial of MN-166 for methamphetamine

Preliminary results from one cognitive performance task, presented in a poster
session, showed significant improvement in measures of sustained attention in
subjects completing a treatment sequence ending with a one-week course of
MN-166 dosing at 100 mg/day versus those subjects completing the treatment
sequence on an inactive control ("placebo").In addition, MN-166 was featured
in a symposium panel titled "Preclinical to Clinical Evidence that Glia and
Neuroinflammation Mediate Drug Abuse and Related Pathologies on Tuesday, June
18 at 10:00 am Pacific. The panel included researchers from UCLA, Columbia
University in New York, and Virginia Commonwealth University. In the
symposium, Dr. Shoptaw summarized results of cardiovascular safety analyses
wherein infusions of methamphetamine administered at placebo, 40 mg/day and
100 mg/day MN-166 regimens.Analyses showed that in the presence of relevant
doses of methamphetamine, MN-166 produced no significant changes in blood
pressure or heart rate.These cardiovascular safety interaction endpoints were
a primary objective in the study design.He also noted that MN-166
administration did not result in any serious or severe adverse events, or
subject discontinuations due to adverse events. These findings provide support
for moving forward with the Phase 2 trial.

"We are very pleased with the continuing safety data for MN-166 and look
forward to advancing our program, focusing on drug addiction indications as
well as progressive multiple sclerosis," said Dr. Yuichi Iwaki, President and
CEO of MediciNova. "Congratulations to Drs. Shoptaw and Heinzerling on their
unwavering efforts to test pharmacotherapies for this devastating disease."

About Methamphetamine Addiction

Methamphetamine is a very addictive stimulant that is closely related to
amphetamine. It is long lasting and toxic to dopamine nerve terminals in the
central nervous system. It is a white, odorless, bitter-tasting powder taken
orally or by snorting or injecting, or a rock "crystal" that is heated and

Methamphetamine increases wakefulness and physical activity, produces rapid
heart rate, irregular heartbeat, and increased blood pressure and body
temperature. Long-term use can lead to memory loss, aggression, psychotic
behavior, heart damage, malnutrition and severe dental problems. All users,
but particularly those who inject the drug, risk infectious diseases such as
HIV/AIDS and hepatitis.

According to the Substance Abuse and Mental Health Services Administration's
(SAMHSA) 2011 National Survey on Drug Use and Health, there are approximately
439,000 methamphetamine abusers in the U.S. An independent study conducted by
the Rand Corporation estimated the economic burden of methamphetamine use in
the U.S. at $23.4 billion in 2005.There are no medications currently approved
by the FDA for the treatment of methamphetamine dependence. Herbert D. Kleber
M.D., founder and Director of the Division on Substance Abuse, New York State
Psychiatric Institute, and Professor of Psychiatry at Columbia University
Medical Center, and a prior Deputy Director at the White House Office of
National Drug Control Policy noted that "there truly is an unmet need for
pharmacotherapy treatment of methamphetamine dependence and the recognition of
such need by the FDA is positive for the field."

About MN-166 Clinical Development in Addiction

Clinical development of MN-166 is ongoing in both methamphetamine addiction
and opioid addiction. Potential utility in alcohol dependence is also under
consideration. The ongoing or pending clinical trials are conducted by some of
the country's leading experts in studying treatments for these drugs of abuse.
A Phase 2 outpatient clinical trial of MN-166 in methamphetamine dependence,
led by investigators at UCLA, has been funded by NIDA.In opioid addiction, a
second NIDA-funded Phase 2a clinical trial of MN-166 in prescription opioid or
heroin abusers is currently ongoing with the investigators at Columbia
University and the New York State Psychiatric Institute.

About MN-166 (ibudilast)

MN-166 has been marketed in Japan and Korea since 1989 to treat
cerebrovascular disorders, including post-stroke complications, and bronchial
asthma. MediciNova licensed MN-166 (ibudilast), from Kyorin Pharmaceutical in
October 2004 for potential utility in relapsing, remitting multiple sclerosis.
MediciNova scientists and collaborators independently established evidence of
ibudilast utility in opioid and methamphetamine addiction as well as chronic
neuropathic pain.Potential utility in progressive multiple sclerosis arose
from certain outcomes of a phase 2 trial reported in 2010.

MN-166 is a first-in-class, orally bioavailable, small molecule
phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration
inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines
including IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory
cytokine IL-10 and neurotrophic factors like GDNF and NGF. It attenuates the
activation of brain glial cells in neurological disorders and that cellular
effect is thought to contribute to its therapeutic action.Accordingly,
MediciNova's development efforts in progressive MS and chronic neuropathic
pain are founded upon both anti-neuroinflammatory and neuroprotective actions
which have been demonstrated in preclinical and clinical data.

MediciNova's issued method-of-use patent for MN-166 for the treatment of
addiction expires no earlier than 2030 in the U.S.In the ongoing and pending
grant-funded MN-166 trials, one of MediciNova's commitments is to provide
delayed-release ibudilast final product.A drug supply collaboration with
Taisho Pharmaceutical Industries, Ltd., owned by Teva Pharmaceuticals, has
expanded to include development of higher dosage strength ibudilast capsules.

About MediciNova

MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet need with a commercial focus on the U.S.
market.MediciNova's current strategy is to focus on its two prioritized
product candidates, MN-166 (ibudilast) for neurological disorders, and MN-221
for the treatment of acute exacerbations of asthma.MN-166 is being developed
in multiple indications, largely through investigator sponsored trials and
outside funding.Proof-of-concept Phase 2b trial(s) in Progressive MS are
pending. MediciNova is engaged in strategic partnering and consortium funding
discussions to support further development of both the MN-221 and MN-166
programs.For more information on MediciNova, Inc., please visit

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding our clinical
development strategies, including future development, statements regarding the
progress of clinical trials, statements regarding expectations for the
ibudilast/MN-166 program, including development of ibudilast/MN-166 for
certain indications and expectations on future progress in the development of
our drug candidates, expected timing of clinical trial results and any
implication as to the results of our development, partnering and funding
efforts, theimplication of patent terms and potential product exclusivity and
the implication that the company will have the ability to execute on its
priorities. These forward-looking statements may be preceded by, followed by
or otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will," "would," or
similar expressions. These forward-looking statements involve a number of
risks and uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking statements.
Factors that may cause actual results or events to differ materially from
those expressed or implied by these forward-looking statements, include, but
are not limited to, risks of obtaining future partner or grant funding for
development of MN-221 and MN-166 and risks of raising sufficient capital when
needed to fund MediciNova's operations and contribution to clinical
development, risks and uncertainties inherent in clinical trials, including
the potential cost, expected timing and risks associated with clinical trials
designed to meet FDA guidance and the viability of further development
considering these factors, product development and commercialization risks,
the uncertainty of whether the results of clinical trials will be predictive
of results in later stages of product development, the risk of delays or
failure to obtain or maintain regulatory approval, risks associated with the
reliance on third parties to sponsor and fund clinical trials, risks regarding
intellectual property rights in product candidates and the ability to defend
and enforce such intellectual property rights, the risk of failure of the
third parties upon whom MediciNova relies to conduct its clinical trials and
manufacture its product candidates to perform as expected, the risk of
increased cost and delays due to delays in the commencement, enrollment,
completion or analysis of clinical trials or significant issues regarding the
adequacy of clinical trial designs or the execution of clinical trials, and
the timing of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to complete
product development plans and MediciNova's ability to obtained third party
funding for programs and raise sufficient capital when needed, and the other
risks and uncertainties described in MediciNova's filings with the Securities
and Exchange Commission, including its annual report on Form 10-K for the year
ended December 31, 2011 and its subsequent periodic reports on Forms 10-Q and
8-K.Undue reliance should not be placed on these forward-looking statements,
which speak only as of the date hereof. MediciNova disclaims any intent or
obligation to revise or update these forward-looking statements.

         Mike Coffee
         Chief Business Officer
         MediciNova, Inc.
         (858) 736-7180
         Stephanie Ashe
         Continuum Health Communications
         (650) 245-0425

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.